Adoptive Cellular Therapy (ACT)
Immatics US, Inc. was launched in 2015 by Immatics and MD Anderson Cancer Center (MDACC) to develop multiple next-generation Adoptive Cell Therapies (ACT) for the treatment of cancer.
Based on both Immatics’ XPRESIDENT® target discovery platform and MDACC’s significant ACT expertise, work is focused on the development of three ACT approaches to treat cancer: ACTolog®, ACTengine®, and ACTallo®.
ACTolog® uses a cancer patient’s own (autologous) T-cells specifically recognizing Immatics’ XPRESIDENT® targets. We cultivate large numbers of these cancer-specific T cells outside the body before being reinfused back into the patient.
Proof-of-concept for the ACTolog® approach has been demonstrated by Prof. Cassian Yee (MD Anderson Cancer Center) in melanoma and high-risk leukemia settings including the observation of objective clinical responses.
ACTengine® involves genetically engineering a patient’s own T cells to express novel T-cell receptors which are specific to Immatics’ XPRESIDENT® targets. Such “reprogrammed” T cells are then cultivated in large numbers outside the body before being reinfused into the patient.
ACTallo® is our next-generation approach. It works the same way as ACTengine® but does not reprogram the patient’s own cells but uses allogenic gamma- delta T cells (non-patient specific) which means they can be used “off-the-shelf” for the quicker treatment of any patient with that particular cancer. This approach has been pioneered by Prof. Laurence Cooper (previously at MD Anderson Cancer Center).